Candel Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 13, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 13, 2025
CADL$9.35-1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
| YEAR ENDEDDECEMBER 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash Flows from Operating Activities: | ||
| Net loss | $(55,177) | $(37,939) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation expense | 990 | 960 |
| Impairment of fixed assets | 41 | 390 |
| Loss on the sale of fixed assets | — | 79 |
| Non-cash stock compensation expense | 5,312 | 3,091 |
| Non-cash lease expense | 274 | 240 |
| Non-cash interest expense | 119 | 103 |
| Change in fair value of warrant liability | 20,802 | (966) |
| Accretion of debt discount | 270 | 323 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 234 | 503 |
| Other assets | 53 | (116) |
| Accounts payable | (185) | 45 |
| Accrued expenses | 757 | (301) |
| Deferred income | — | (192) |
| Lease liability | (513) | (464) |
| Net cash used in operating activities | (27,023) | (34,244) |
| Cash Flows from Investing Activities: | ||
| Purchase of fixed assets | (16) | (457) |
| Proceeds from the sale of fixed assets | — | 177 |
| Net cash used in investing activities | (16) | (280) |
| Cash Flows from Financing Activities: | ||
| Proceeds from issuance of common stock and accompanying pre-funded warrants in public offering, net of issuance costs | 85,928 | — |
| Proceeds from sale of common stock through at-the-market offerings, net of issuance costs | 15,830 | — |
| Proceeds from option exercises | 1,689 | — |
| Principal payments on term loan | (9,167) | — |
| Payments related to tax withholding for vested restricted stock units | — | (121) |
| Net cash provided by (used in) financing activities | 94,280 | (121) |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 67,241 | (34,645) |
| Cash, cash equivalents and restricted cash at beginning of period | 35,679 | 70,324 |
| Cash, cash equivalents and restricted cash at end of period | $102,920 | $35,679 |
| Supplemental cash flow information: | ||
| Cash paid for interest | $1,795 | $2,148 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.